Cre-loxP, a powerful tool for preclinical cancer research, possesses intrinsic pitfalls that can alter result accuracy, according to an editorial paper in Oncoscience. Cancer and other diseases could ...

“One limitation [of Cre-LoxP], the focus of this editorial, is the potential loss of fidelity of Cre recombinase expression especially in the context of modeling cancer in mice.” “It is based on ...